Psoriasis and Spondyloarthritides: The Evolving Biologics Landscape

CME Activities

• Emerging Therapies for Psoriatic Arthritis and Axial Spondyloarthritis: An Update From Milan
  Medscape Education, June 2023
  Are you up to date on the new and emerging therapies in PsA and axSpA?
  0.25 CME
• Raising the Bar: Optimizing Outcomes in Spondyloarthritis
  Medscape Education, June 2023
  What are appropriate treatment goals to achieve disease suppression in your patients with spondyloarthritis?
  0.25 CME

  0.25 ABIM MOC
• Data Deep Dive: What’s New in Biologic Therapies for Psoriatic Arthritis and Axial Spondyloarthritis?
  Medscape Education, March 2023
  Did you know that there are now data from a head-to-head study comparing different biologics in patients with ankylosing spondylitis?
  0.25 CME
• Optimizing Outcomes for Spondyloarthritis: Focus on Interleukin-23/-17 Inhibitors
  Medscape Education, March 2023
  What's new in treatments for spondyloarthritis? Learn more about the rationale for novel therapies and the latest data.
  0.75 CME

  0.75 ABIM MOC
• Where Are We Now in the Use of Interleukin-17 Inhibitors for Psoriatic Disease?
  Medscape Education, January 2023
  Can you navigate the increasingly complex treatment landscape for psoriasis and psoriatic arthritis (PsA)?
  0.75 CME

  0.75 ABIM MOC
• Axial Spondyloarthritis: What Do You Know?
  Medscape Education, December 2022
  Did you know that patients with axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) experience more pain and fatigue compared with patients with rheumatoid arthritis (RA)?
  0.25 CME
• Raising the Bar: Implementing Treatment Goals in Clinical Practice for Spondyloarthritis
  Medscape Education, December 2022
  Do you know how to set treatment goals for your patient with spondyloarthritis?
  0.50 CME

• Mechanism of action of agents targeting the IL-17 pathway in psoriasis
  Medscape Education, February 2021
• Biologic Treatment Selection for Psoriatic Disease in a Complex Treatment Landscape
  Medscape Education, September 2023
  Did you know that up to a third of patients with psoriasis go on to develop psoriatic arthritis in the long-term?
  0.25 CME

  0.25 ABIM MOC
• Where Are We Now in the Use of Interleukin-17 Inhibitors for Psoriatic Disease?
  Medscape Education, January 2023
  Can you navigate the increasingly complex treatment landscape for psoriasis and psoriatic arthritis (PsA)?
  0.75 CME

  0.75 ABIM MOC
• Biologics Targeting the IL-23/IL-17 Pathway in Psoriatic Disease: Treating Beyond the Skin
  Medscape Education, November 2022
  Did you know that scalp psoriasis is associated with an increased risk of psoriatic arthritis (PsA)?
  0.25 CME